Concordia International Corp CXR
|
|
|
- Sandra Sullivan
- 6 years ago
- Views:
Transcription
1 Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.72 ] % $ mil 168, , Stock Price XTSE:CXR: % 2018 Morningstar s Take Key Stats Stock Ind Avg Price/Earnings TTM Price/Book Price/Sales TTM Rev Growth (3 Yr Avg) Net Income Growth (3 Yr Avg) Operating Margin % TTM Net Margin % TTM ROA TTM -53 ROE TTM Debt/Equity Fair Value Estimate $ - Consider Buying $ - Consider Selling $ - Fair Value Uncertainty Economic Moat Stewardship Growth Z Profitability B Morningstar Credit Rating Relative to Industry - Avg + Dividends Declared Date 13/05/2016 Ex-Dividend Date 13/07/2016 Latest Indicated Dividend Amount 0.08 Projected Yield % Recent Dividends & Type Amount Splits 07/13/2016 Cash Dividends /13/2016 Cash Dividends /13/2016 Cash Dividends /13/2015 Cash Dividends Competitors Name Price % Chg TTM Sales $ mil Concordia International ] 646 Corp Theratechnologies Inc ] 34 Prometic Life Sciences Inc ] 29 Cronos Group Inc [ 3 Emerald Health Therapeutics Inc [ 1 Aurinia Pharmaceuticals Inc [ 0 Recommendations Current 1.0 Total Analysts: Buy Hold Sell Ownership Fund Owners Star Rating % Shares Held % Total Assets Financials Annual Quarterly Income Statement Revenue Operating Income Net Income -1, Earnings Per Share Shares Outstanding Balance Sheet Current Assets Non Current Assets 3,018 4, ,005 3,752 Total Assets 3,732 5, ,652 4,230 Current Liabilities Total Liabilities 4,109 4, ,129 3,929 Stockholders' Equity , , Cash Flow Cash From Operations Capital Expenditures
2 Morningstar Analyst Rating Page 2 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.72 ] % $ mil 168, , Financials Annual Quarterly Free Cash Flow In millions except "EPS". Currency in USD.
3 Page 3 of 5 Industry Classification NAICS Pharmaceutical Preparation Manufacturing (325412) SIC Pharmaceutical and Medicine Industry (3741);Pharmaceutical Preparations (2834) ISIC Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (2100) Operation Details Fiscal Year Ends CIK Year Established Employees (31/12/2016) 516 Full Time Part Time Auditor (31/12/2016) PricewaterhouseCoopers LLP Legal Advisor () Key Executives Arijit Mookerjee/Managing Director and Chief Financial Officer of CPI and CLI; Allan Oberman/Chief Executive Officer and Director; Francesco Tallarico/Chief Legal Officer and Secretary; Adeel Ahmad/Chief Financial Officer of AMCo; Wayne Kreppner/Chief Operating Officer Company Profile Concordia International Corp is a specialty pharmaceutical company which owns a diversified portfolio of branded and generic prescription products. It focuses on generic and legacy pharmaceutical products. 30-day Avg Volume Market Cap Net Income Sales Sector Industry Stock Style Direct Investment Dividend Reinvestment 0.1Mil 35.6Mil Mil 0.6Bil Healthcare Biotechnology 3 Small Value No No
4 Page 4 of 5 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage Concordia International Corp 44-1, Cronos Group Inc (CAD) 1, Prometic Life Sciences Inc (CAD) 1, Aurinia Pharmaceuticals Inc (CAD,USD) , Emerald Health Therapeutics Inc (CAD) , Theratechnologies Inc (CAD) Zymeworks Inc (CAD,USD) ABcann Global Corp (CAD) , Neptune Technologies & Bioressources Inc (CAD) VBI Vaccines Inc (CAD,USD) , Helius Medical Technologies Inc (CAD,USD) Resverlogix Corp (CAD,USD) CohBar Inc (USD) Immunovaccine Inc (CAD) , MYM Nutraceuticals Inc (CAD) Neurokine Pharmaceuticals Inc (CAD,USD) Fennec Pharmaceuticals Inc (CAD,USD) CannaRoyalty Corp (CAD) Valens Groworks Corp (CAD) , , ,198.1 THC Biomed International Ltd (CAD) , Scythian Biosciences Corp (CAD) Covalon Technologies Ltd (CAD) Trillium Therapeutics Inc (CAD) Tetra Bio Pharma Inc (CAD) Medicure Inc (CAD) Emblem Corp (CAD) ProMIS Neurosciences Inc (CAD) , , Matica Enterprises Inc (CAD) Helix BioPharma Corp (CAD) Wildflower Marijuana Inc (CAD) Aptose Biosciences Inc (CAD) Oncolytics Biotech Inc (CAD) Beleave Inc (CAD) Intelgenx Technologies Corp (CAD,USD) Cardiome Pharma Corp (CAD,USD) Abattis Bioceuticals Corp (CAD) , ,605.4 Canada House Wellness Group Inc (CAD) Liberty Leaf Holdings Ltd (CAD) Medicenna Therapeutics Corp (CAD) ,186.8 Ceapro Inc (CAD) Kalytera Therapeutics Inc (CAD,USD) ,690.8 Antibe Therapeutics Inc (CAD) BELLUS Health Inc (CAD) AEterna Zentaris Inc (CAD,USD) , Devonian Health Group Inc (CAD) DiaMedica Therapeutics Inc (CAD,USD) Biocure Technology Inc (CAD) bioasis Technologies Inc (CAD) Eviana Health Corp (CAD) IntelliPharmaCeutics International Inc (CAD,USD) Acasti Pharma Inc (CAD) , , D/E
5 Page 5 of 5 Industry Peers Arch Biopartners Inc (CAD) Pediapharm Inc (CAD) Microbix Biosystems Inc (CAD) Burcon NutraScience Corp (CAD) , Naturally Splendid Enterprises Ltd (CAD) Veritas Pharma Inc (CAD) Sirona Biochem Corp (CAD) , Liberty Biopharma Inc (CAD) Portage Biotech Inc (USD) Delivra Corp (CAD) Quest PharmaTech Inc (CAD) ImmunoPrecise Antibodies Ltd (CAD) Nanosphere Health Sciences Inc (CAD) MedMira Inc (CAD) Hemostemix Inc (CAD) ,667.0 Revive Therapeutics Ltd (CAD) Cotinga Pharmaceuticals Inc (CAD) ,607.6 Therma Bright Inc (CAD) ,288.5 Ortho Regenerative Technologies Inc (CAD) Vodis Pharmaceuticals Inc (CAD) , BriaCell Therapeutics Corp (CAD) Advanced Proteome Therapeutics Corp (CAD,USD) RepliCel Life Sciences Inc (CAD) Callitas Health Inc (CAD) Crescita Therapeutics Inc (CAD) , Medifocus Inc (CAD,USD) Pascal Biosciences Inc (CAD) ,001.6 PreveCeutical Medical Inc (CAD) 7 0 Vaxil Bio Ltd (CAD) Ibex Technologies Inc (CAD) Kane Biotech Inc (CAD) , Novoheart Holdings Inc (CAD) ,995.9 Eastwood Bio-Medical Canada Inc (CAD) Innovotech Inc (CAD) Pacgen Life Science Corp (CAD) ico Therapeutics Inc (CAD) Waverley Pharma Inc 1 Biosenta Inc (CAD) , Avidus Management Group Inc (CAD,USD) Novelion Therapeutics Inc (CAD,USD) Bradmer Pharmaceuticals Inc (CAD,USD) InNexus Biotechnology Inc (CAD) -4-33,603.6 Phivida Holdings Inc (CAD) -2-13, Endocan Solutions Inc (CAD) Industry Average , ,194.1
RGC Resources Inc RGCO
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 27.08 [-0.88-3.15 % $ 27.71 27.00-27.85
CenterPoint Energy Inc CNP
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 28.86 [-0.15-0.52 % $ 28.97 28.66-28.97
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF [ % - 0.00-0.00 mil -- Stock Price 2017-01-02-2017-08-03
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 47.65 [-0.40-0.83 % $ 47.95 47.65-48.65
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 52.70 [-0.70-1.31 % $ 53.55 52.10-53.85
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 65.46 ]0.14 0.21 % $ 65.35 64.85-66.05
National Grid PLC ADR NGG
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 57.57 ]0.42 0.73 % $ 57.40 57.21-57.68
Stora Enso Oyj ADR SEOAY
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 16.13 ]0.21 1.32 % $ 16.15 16.12-16.15
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 9.18 [-0.01-0.11 % $ 9.10 9.10-9.22 7.04-10.31
Tanger Factory Outlet Centers Inc SKT
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 22.94 ]0.12 0.53 % $ 22.93 22.26-23.03
LDK Solar Co Ltd ADR LDKYQ
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.03 ]0.00 14.28 % $ 0.02 0.02-0.03 0.00-0.04
Kimco Realty Corp KIM
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 14.31 [-0.21-1.45 % $ 14.41 14.25-14.52
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 83.76 ]2.11 2.58 % $ 82.16 81.74-83.90
Anheuser-Busch InBev SA/NV ADR BUD
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 111.76 [-2.34-2.05 % $ 112.82 111.18-112.87
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 136.10 ]0.07 0.05 % $ 136.62 135.78-136.63
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 50.69 ]1.67 3.41 % $ 49.19 48.87-50.88
EQM Technologies & Energy Inc EQTE
Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.02 ]0.00 5.00 % $ 0.02 0.02-0.02 0.01-0.05
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 169.23 [-1.85-1.08 % $ 170.52 169.22-170.59
Microchip Technology Inc MCHP
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 85.16 ]1.24 1.48 % $ 84.81 83.67-85.22
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 43.30 ]0.22 0.51 % $ 43.35 43.11-43.58
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 58.56 [-1.30-2.17 % $ 59.41 58.28-59.97
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 46.23 ]0.23 0.50 % $ 46.00 45.94-46.36
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 66.47 ]0.44 0.67 % $ 66.04 65.50-66.60
Trailing PE Forward PE Buy 10 Analysts. 1-Year Return: -6.2% 5-Year Return: --
KNIGHT ERAPEUTICS INC (-T) Last Close 7.86 (CAD) Avg Daily Vol 88,400 52-Week High 8.81 Trailing PE 49.8 Annual Div -- ROE 2.2% LTG Forecast -- 1-Mo -4.4% October 31 TORONTO Exchange Market Cap 1.1B 52-Week
Horizons Marijuana Life Sciences Index ETF (HMMJ, HMMJ.U:TSX)
Interim Report June 30, 2018 Horizons Marijuana Life Sciences Index ETF (HMMJ, HMMJ.U:TSX) ACTIVE BENCHMARK BETAPRO Innovation is our capital. Make it yours. www.horizonsetfs.com Contents MANAGEMENT REPORT
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 18.50 ]0.38 2.07 % $ 18.50 18.43-18.65
CIF Stock Recommendation Report (Spring 2014)
Date: 2/28/14 Analyst Name: Anthony Ledesma & Mason Yang CIF Stock Recommendation Report (Spring 2014) Company Name and Ticker: UnitedHealth Group (UNH) Section (A) Investment Summary Recommendation Buy:
CIF Stock Recommendation Report (Fall 2012)
Date:_10/9/2012 Analyst Name: Scott R. Mertens CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker:_JPMorgan Chase_(JPM) Section (A) Summary Recommendation Buy: Yes Target Price: $49.24
COMPANY PRESENTATION - HEALTHCARE. Anthony Rogers, Thomas Rosol & Dylan Seymour
COMPANY PRESENTATION - HEALTHCARE Anthony Rogers, Thomas Rosol & Dylan Seymour Agenda Overview Business Analysis Financial Analysis Valuation Analysis Company Analysis Recommendation 2 S&P 500 Sector Weight
CIF Stock Recommendation Report (Fall 2012)
Date: Saturday, November 10, 2012 Analyst Name: Fausto Guillén Aguilar Jr. CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: International Business Machines Corp IBM Section (A) Summary
CIF Stock Recommendation Report (Fall 2012)
Section (A) Summary CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: Boeing BA Recommendation Buy: Yes Target Price: $83.00 Sector: Industrials Industry: Aerospace & Defense Market
CIF Stock Recommendation Report (Fall 2012)
Date: 10/13/2012 Analyst Name: Ryan Ellingsen CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: Colgate-Palmolive Company (CL) Section (A) Summary Recommendation Buy: Hold Target Price:
United Technologies Corp UTX
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 127.57 [-0.55-0.43 % $ 128.32 127.57-128.49
Market Capitalization $2.4 Billion. Sector: Health Care Sub-Industry: Biotechnology Source: S&P Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F December 3, 2017 SDAQ: HOLD HOLD RATING SINCE 03/02/2017 BUSINESS DESCRIPTION Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing
Market Capitalization $3.6 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of R-based
For this assignment: 100 for the write-up for question numbers 1 through 5; 100 for the final recommendation
Assignment #7: Multiples valuation Date due: April 20, 2015, 12noon : 1) the write-up for the question numbers 1 through 5 2) the initial draft of your recommendation. Please bring a printed copy to class
International Business Machines Corp IBM
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 155.41 ]0.60 0.39 % $ 154.97 154.57-155.89
CIF Stock Recommendation Report (Fall 2012)
CIF Stock Recommendation Report (Fall 2012) Date: 10/16/2012 Analyst Name: Matt Leid Company Name and Ticker: Salesforce.com (CRM) Section (A) Summary Recommendation Buy: Yes No Target Price: NA Stop-Loss
CIF Stock Recommendation Report (Fall 2012)
Section (A) Summary CIF Stock Recommendation Report (Fall 2012) Recommendation: Do Not Buy Recommended Buy Price: $69 Sector: Industrials Company Name and Ticker: Caterpillar Inc. (CAT) Industry: Farm
Market Capitalization $7.6 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BIO BUSINESS DESCRIPTION Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical
Trailing PE Forward PE Buy 10 Analysts. 1-Year Return: -5.1% 5-Year Return: 3328%
Last Close 13.71 (CAD) Avg Daily Vol 9.0M 52-Week High 22.00 Trailing PE 41.6 Annual Div -- ROE 7.7% LTG Forecast -- 1-Mo 38.2% 2019 February 21 TORONTO Exchange Market Cap 3.2B 52-Week Low 4.76 Forward
Sunoco, Inc. SUN [NYSE]
![Sunoco, Inc. SUN [NYSE]](/thumbs/91/104511352.jpg "Sunoco, Inc. SUN [NYSE]")
? Sunoco, Inc. SUN [NYSE] High oil prices and a weak consumer environment should translate into lower margins for Sunoco. heavy sour crude discounts will remain strong; consequently, the financial performance
Market Capitalization $6.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY SDAQ: ICLR BUY RATING SINCE 03/26/2013 TARGET PRICE $151.83 ICLR BUSINESS DESCRIPTION ICON Public Limited Company, a contract
Danaher Corporation DHR [XNYS] QQQ
![Danaher Corporation DHR [XNYS] QQQ](/thumbs/77/76479167.jpg "Danaher Corporation DHR [XNYS] QQQ")
? Danaher Corporation DHR [XNYS] QQQ 5083 USD 5600 USD 3360 USD 8680 USD High Narrow A- Diversified Industrials Core Revenue Growth Continues to Weaken for Danaher in First Quarter by Daniel Holland Senior
Global Blood Therapeutics Inc GBT
Global Blood Therapeutics Inc GBT Page 1 of 5 Last Close Fair Value Q Market Cap Industry of Domicile 29 Nov 217 3 Nov 217 2: UTC 29 Nov 217 37.4 36.84 1,634.4 Mil d Healthcare Biotechnology USA United
CIF Stock Recommendation Report (Fall 2012)
Date: 10/11/12 Analyst Name: Joseph Brendel CIF Stock Recommendation Report (Fall 2012) Section (A) Summary Company Name and Ticker: Prudential (PRU) Recommendation Buy: No Target Price: 35 Sector: Financials
XBI SPDR S&P BIOTECH ETF
SPDR S&P BIOTECH ETF ETF.com segment: Equity: U.S. Biotech Competing ETFs: FBT, BBC, CNCR, BBP, IBB Related ETF Channels: North America, Biotech, Equal-Weighted, Smart-Beta ETFs, S&P Biotechnology Select
Investing.xls debt charts 1 10/4/2010
Company Explorer - Debt Summary Service Corp. International SCI 817565104 2797560 NYSE Common stock Other Consumer Services 04-Oct-2010 ICMA / Mergent / Reuters Global Fundamentals U.S. Dollar 600 500
Healthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang
Healthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang Agenda Sector Overview SIM Portfolio Overview Additional Companies Assessed Stocks Recommendation Healthcare Sector:
CIF Sector Recommendation Report (Spring 2013)
Date: 4/1/2013 Analyst: Jacob Allen CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 3/13/2013 3/26/2013 Section (A) Sector Performance Review Copy/paste Sector Review Spreadsheet
CIF Stock Recommendation Report (Fall 2012) Summary
Date: 11/6/2012 Analyst Name: Kyle Temple CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: Dover Corp Summary DOV Recommendation Buy: Yes No Target Price: $65.00 Sector: Industrials
Market Capitalization $7.4 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F BUY December 31, 2017 BUY RATING SINCE 05/06/2016 TARGET PRICE $80.00 WPC BUSINESS DESCRIPTION W. P. Carey Inc. is a leading internally-managed net
Ratios Current Industry Historical Median
[1] 51.90 Medical Devices Market Cap: 820 Mil Draegerwerk AG & Co KGaA provides medical and safety technology. The Company has two main divisions: safety division and medical division. It provides Fire
Market Capitalization $3.2 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 08/15/2017 TARGET PRICE $33.32 BUSINESS DESCRIPTION Stantec Inc. provides professional consulting services
Danaher Corporation DHR [XNYS] QQQ
![Danaher Corporation DHR [XNYS] QQQ](/thumbs/77/76479143.jpg "Danaher Corporation DHR [XNYS] QQQ")
? Danaher Corporation DHR [XNYS] QQQ Danaher's Third Quarter Below Expectations, Cash Flow Remains Strong by Daniel Holland Senior Stock Analyst Analyst covering this company do not own its stock. Pricing
Morningstar Stock Report. Carter's CRI. 2 Quote/Snapshot 3 Analyst Report 5 Financials 6 Valuation 7 Ownership
Morningstar Stock Report 2 Quote/Snapshot 3 Analyst Report 5 Financials 6 Valuation 7 Ownership Release date 21 Mar 2007 NASD Members: For internal use or client reporting purposes only Page 2 of 7 Quote/Snapshot
Trailing PE Forward PE Buy 28 Analysts. 1-Year Return: -4.4% 5-Year Return: -1.0%
GILEAD SCIENCES INC (-O) Last Close 69.20 (USD) Avg Daily Vol 7.1M 52-Week High 89.54 Trailing PE 57.7 Annual Div 2.28 ROE 6.7% LTG Forecast -5.0% 1-Mo -9.3% November 16 NASDAQ Exchange Market Cap 89.5B
CIF Stock Recommendation Report (Fall 2012)
CIF Stock Recommendation Report (Fall 2012) Date: Nov 27 th 2012 Analyst Name: Tung Linh Company Name and Ticker: W.W. Grainger, Inc. (GWW) Section (A) Summary Recommendation Buy: No Target Price: Stop-Loss
EQUITY RESEARCH. February 27, 2002 S&P Sector Cons. Staples Industry Household Products. Market Cap. MSN money
M.A. W M.A. WRIGHT FUND EQUITY RESEARCH Nat Apihunpunyakij Kimberly-Clark Corp. NYSE: KMB Buy apihunpu@rice.edu February 27, 2002 S&P Sector Cons. Staples Industry Household Products MARKET DATA Price
Market Capitalization $507.9 Million
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate $ BUY SDAQ: WI BUY RATING SINCE 11/30/2010 TARGET PRICE $174.43 WI BUSINESS DESCRIPTION Winmark Corporation operates as a franchisor
SOPHARMA INDUSTRY: PHARMACEUTICALS RESULTS ANALYSIS BUY RECOVERY SPEEDING UP EQUITY RESEARCH BULGARIA DATE: JULY 18 TH 2017
EQUITY RESEARCH BULGARIA SOPHARMA INDUSTRY: PHARMACEUTICALS RECOVERY SPEEDING UP SOPHARMA S FUNDAMENTALS ARE RECOVERING WELL ABOVE EXPECTATIONS WITH EXCELLENT Q1 17 TOP LINE AND FURTHER IMPROVEMENT IN
Current Price: $ WK Hi: $ WK Low: $55.21 EBO Valuation: $73.07
Date: April 12 th, 2014 Analyst Name: Trevor Russell CIF Stock Recommendation Report (Spring 2014) Company Name and Ticker: CVS Caremark Corporation (CVS) Section (A) Investment Summary Recommendation
EPS = (Total Company Earnings) / (Shares Outstanding)
Basic Ratios Ratios are a common tool investors use to relate a stock's price with an element of the underlying company's performance. These quick and dirty ratios can be useful in their own way, as long
Ratios Current Industry Historical Median
[1] $ 97.99 Retail - Defensive - Discount Stores Market Cap: $ 289,153 Mil Walmart Inc operates retail stores in various formats under various banners. Its operations comprise of three reportable business
Acadia Pharmaceuticals. Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia
Acadia Pharmaceuticals Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia Introduction: ACAD Acadia Pharmaceuticals ACAD Small cap, relatively young, bio pharmaceutical
Trailing PE Forward PE Buy 13 Analysts. 1-Year Return: 5.0% 5-Year Return: 115.5%
ALGONQUIN POWER & UTILITIES (-T) Last Close 13.75 (CAD) Avg Daily Vol 950,518 52-Week High 14.40 Trailing PE 25.9 Annual Div 0.67 ROE 7.0% LTG Forecast 6.1% 1-Mo 3.3% September 21 TORONTO Exchange Market
Market Capitalization $37.6 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 09/28/2004 TARGET PRICE $45.29 BUSINESS DESCRIPTION Provides chemical, plastic and agricultural products
Union Pacific Corporation (NYSE: UNP)
Sep 06, 2016 Union Pacific Corporation (NYSE: UNP) $95.28 USD ( As of 09/05/16 ) Zacks Rank 4-Sell Style:Value: Growth: Momentum: VGM: Data Overview 52 Week High-Low $97.05 - $68.79 20 Day Average Volume
Trailing PE Forward PE -- NA 0 Analysts. 1-Year Return: 26.2% 5-Year Return: 263.1%
RICHARDS PACKAGING INCOME (-T) Last Close 36.75 (CAD) Avg Daily Vol 3,844 52-Week High 40.68 Trailing PE 25.0 Annual Div 1.32 ROE 19.0% LTG Forecast 1-Mo -8.2% October 29 TORONTO Exchange Market Cap 405M
CIF Stock Recommendation Report (Spring 2013)
Date: 2/11/2013 Analyst Name: Bradley Barham CIF Stock Recommendation Report (Spring 2013) Section (A) Summary Company Name and Ticker: CNH Global N.V. (CNH)_ Recommendation Buy: Yes No Target Price: 55.00
Market Capitalization $3.0 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. STOCK PERFORMANCE
RECOMMENDATION: BUY PRICE: $ HIGHLIGHTS. Founded in 1945 as Sigma Chemical Company to manufacture saccharin
RECOMMENDATION: BUY May 13, 2009 Sigma-Aldrich Corp. 3050 Spruce Street St Louis, MO 63103 United States Phone: 1-800-521-8956 Web Site: www.sigma-aldrich.com PRICE: $ 40.12 SECTOR: CHEMICALS HIGHLIGHTS
Market Capitalization $1.9 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION is a real estate investment trust, or REIT, which primarily owns properties located throughout the United
CIF Stock Recommendation Report (Spring 2013)
Date: 3/22/13 Analyst Name: Jacob Allen CIF Stock Recommendation Report (Spring 2013) Company Name and Ticker: CareFusion Corp. (CFN) Section (A) Summary Recommendation Buy: Yes No Target Price: Stop-Loss
Market Capitalization $5.4 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years BUY HOLD BUY HOLD BUY
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate OHI BUSINESS DESCRIPTION Omega is a real estate investment trust investing in and providing financing to the long-term care
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 265.88 ]0.73 0.28 % $ 265.26 264.53-266.57
Market Capitalization $38.6 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F BUY December 24, 2017 BUY RATING SINCE 12/21/2010 TARGET PRICE $155.60 BUSINESS DESCRIPTION Ecolab Inc. provides water, hygiene, and energy technologies
CIF Stock Recommendation Report (Spring 2015)
Date: 3/3/2015 Analyst Name: Connor Black and Ali Al-Lawati CIF Stock Recommendation Report (Spring 2015) Company Name and Ticker: Danaher (DHR) Section (A) Investment Summary Recommendation Buy: Yes Target
Market Capitalization $16.7 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F BUY December 3, 2017 BUY RATING SINCE 11/30/2010 TARGET PRICE $188.87 BUSINESS DESCRIPTION Cintas Corporation provides corporate identity uniforms
CIF Stock Recommendation Report (Spring 2013)
Date: 4/08/2013 Analyst Name: Frank McLaughlin CIF Stock Recommendation Report (Spring 2013) Section (A) Summary Company Name and Ticker: Monsanto Co. (MON) Recommendation Buy: Yes Target Price: $115 Sector:
CIF Stock Recommendation Report (Fall 2012)
Date: 11/4/12 Analyst Name: Trevor Boren CIF Stock Recommendation Report (Fall 2012) Company Name: CVS Caremark Corp. Ticker: CVS Section (A) Summary Recommendation Buy: Yes No Target Price: N/A Stop-Loss
Market Capitalization $3.0 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Aspen Insurance Holdings Limited, through its subsidiaries, engages in insurance and reinsurance businesses
Market Capitalization $374.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 03/30/2012 TARGET PRICE $161.28 BUSINESS DESCRIPTION Johnson & Johnson, together with its subsidiaries,
Market Capitalization $6.5 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Endurance Specialty Holdings Ltd., through its subsidiaries, underwrites specialty lines of personal and
Market Capitalization $21.8 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 12/07/2010 TARGET PRICE $85.63 BUSINESS DESCRIPTION Republic Services, Inc., together with its subsidiaries,
CIF Stock Recommendation Report (Fall 2012) MS Consider Buying: 49. If Less Than 8 WK, next Earnings Ann. Date: Short Interest Ratio: 1.
Date: October 14 2012 Analyst Name: Justin L. Jaena CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker:_BBBY Section (A) Summary Recommendation Buy: Yes Target Price: 70 Stop-Loss Price:
Utilities: Company Presentation. Xingning Xu Yingxing Ye Jing You
Utilities: Company Presentation Xingning Xu Yingxing Ye Jing You Agenda Portfolio Overview NRG Stock Pitch SO Stock Pitch AEP Stock Pitch SJI Stock Pitch Recommendation Recap Q&A Portfolio Overview Asset
Research Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Financial Performance Analysis of Sun Pharma. V Srinivasa Kumar*, R Renganathan, C Vijaya Banu, and V Vijaya Anand. Faculty at School
Trailing PE -- Forward PE Buy 6 Analysts. 1-Year Return: -5.7% 5-Year Return: 710.7%
ING GROUP (-AE) Last Close 0.95 (EUR) Avg Daily Vol 11.9M 52-Week High 1.62 Trailing PE -- Annual Div -- ROE -112.3% LTG Forecast -- 1-Mo 1.9% November 01 AMSTERDAM Exchange Market Cap 551M 52-Week Low
Aphria Inc. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED AUGUST 31, 2017 AND AUGUST 31, 2016
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED AUGUST 31, AND AUGUST 31, 2016 (Unaudited, expressed in Canadian Dollars, unless otherwise noted) Notice of No Auditor Review
Market Capitalization $371.0 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION organ Chase & Co. operates as a financial services company worldwide. It operates through Consumer & Community
Large Cap Value Dividend Select: Performance & Commentary
Large Cap Value Dividend Select: Performance & Commentary PERFORMANCE SUMMARY The strategy returned -10.59% before fees in the fourth quarter, outperforming the Russell 1000 Value Index s return of -11.72%.
Market Capitalization $2.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate HOLD HOLD RATING SINCE 06/12/2012 BUSINESS DESCRIPTION No company description available. STOCK PERFORMANCE (%) 3 Mo. 1 Yr. 3
Market Capitalization $11.6 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 01/17/2013 TARGET PRICE $168.92 BUSINESS DESCRIPTION Inc., together with its subsidiaries, provides products
CIF Stock Recommendation Report (Spring 2013)
Date: February 6, 2013 Analyst Name: Matt Leid CIF Stock Recommendation Report (Spring 2013) Section (A) Summary Company Name and Ticker: Noble Corporation (NE) Recommendation Buy: Yes No Target Price:
Market Capitalization $69.7 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. It operates through
American Capital, Ltd. ACAS [Nasdaq]
![American Capital, Ltd. ACAS [Nasdaq]](/thumbs/78/77620606.jpg "American Capital, Ltd. ACAS [Nasdaq]")
? American Capital, Ltd. ACAS [Nasdaq] Currency amounts expressed with "$" are in U.S. dollars (USD) unless otherwise denoted. American Capital Declares Dividend by Jason Ren Associate Stock Analyst Analysts
CIF Stock Recommendation Report (Fall 2012)
Date: 10/11/12 Analyst Name: Matthew Landen CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: UnitedHealth Group Inc (UNH) Section (A) Summary Recommendation Buy: No Target Price: Stop-
Market Capitalization $1.7 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 01/17/2013 TARGET PRICE $59.66 BUSINESS DESCRIPTION Ameris Bancorp operates as the holding company for
Zacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive January 29, 2018 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago,